BIEL: The 2026 Story Stock With a Multi‑Stream Royalty Engine
BIEL Becomes the Story Stock for 2026 @ PPS = .003
A move to .003 represents a 3,000% gain from .0001 — outperforming the 10‑year percentage gains of Apple, Amazon, Netflix, Microsoft, Google, and others. We’re already 10% of the way there. The moment this breakout occurs, BIEL/Electrome will receive millions of dollars in free publicity, igniting global awareness and accelerating sales. When the narrative flips, big money will chase the stock.
The BIEL Quantum Leap
BIEL is positioned to achieve in months what took Amazon, Netflix, Apple, Google, Tesla, and Nvidia decades to accomplish.
If BIEL delivers $2.5M in net profit and convinces investors of sustainable, disruptive growth, it could theoretically command a $2.5B market cap (PPS = $0.10). That’s a 1000× P/E multiple, driven by narrative momentum and valuation leverage — similar to Nvidia’s 100,000% rise from its all‑time low.
The quantum leap hinges on one thing:
Transforming investor perception.
If BIEL aligns profitability with a bold, disruptive vision (hello Electrome), the market could reward it with exponential valuation leverage — turning a sub‑penny stock into a medtech powerhouse.
Profitability Is Within Reach
BIEL has already demonstrated how close it is:
Q3 2021 net income: $22,381
Revenue: $414,700 (includes: $100K COVID relief)
Given BIEL’s ultra‑lean operating model, sustained profitability is not theoretical — it’s imminent.
BIEL’s Fastest Path to Success
1. Hit $400K in quarterly revenue
Historical data shows this level supports consistent profitability.
Even the expectation of reaching $400K/quarter could push PPS to copper.
2. Reach $1.5M in annual revenue
Confirms sustainable growth and strengthens investor confidence.
3. Leverage the new U.S. distributor
If investors value the partnership at even $300K, PPS exits the trips.
At a $1M valuation, PPS hits copper.
Share Price Projection
Once profitability is achieved (or imminent), PPS is projected to hit copper ($0.01+).
For every additional $2.5M in annual profit, PPS could rise by $0.01 (P/E = 100).
Valuation Scenarios
.001 — Technical breakout (Golden Cross .0003, Blue‑Sky .0006)
.003 — 3,000% gain when U.S. distributor news goes viral
.01 — Profitability confirmed
.02 — $5M profit
.04 — $10M profit (or $1M × 1000 P/E)
.10 — $25M profit (or $2.5M × 1000 P/E)
$1.00 — After debt payoff + buyback
Tax Advantage: A Hidden Accelerator
BIEL holds a $40M tax‑loss carryforward, meaning the first $40M in profits are tax‑free — accelerating net profitability and preserving cash during early growth.
BIEL’s Multi‑Stream Royalty Revenue Model
BIEL is no longer a single‑product company. It is evolving into a pure‑IP royalty engine with four monetizable product lines plus a clinical multiplier.
1️⃣ ActiPatch — Consumer Retail (Electrome‑Driven)
Where it sells: Pharmacies, online retail, wellness channels
Partner: Electrome
Royalty: ~$2 per unit
Volume: 250,000–1,000,000 units
Annual revenue to BIEL: $500K – $2M
2️⃣ RecoveryRx — Clinical / Post‑Surgical (VLMS‑Driven)
Where it sells: Hospitals, surgical centers, orthopedic practices
Partner: VLMS Global Healthcare
Royalty: $5–$7 per unit
Volume: 50,000–200,000 units
Annual revenue to BIEL: $300K – $1.4M
3️⃣ RecoveryRx Veterinary — High‑Margin Niche
Where it sells: Veterinary surgery, equine medicine, companion‑animal pain
Partner: VLMS or a dedicated veterinary distributor
Royalty: $5–$7.50 per unit
Volume: 20,000–100,000 units
Annual revenue to BIEL: $100K – $750K
4️⃣ Vagus Nerve Stimulation Device — Patent Pending
Applications: Anxiety, depression, PTSD, inflammation, autonomic dysfunction
Partner: Electrome, VLMS, or a new neuromodulation partner
Royalty: $10–$15 per unit
Volume: 50,000–500,000 units
Annual revenue to BIEL: $500K – $5M
5️⃣ Phantom Limb Pain Study — Clinical Validation Multiplier
Not a product — a value amplifier. It strengthens:
VA + military adoption
Insurance reimbursement
Hospital credibility
Pricing power
Revenue impact: +$300K annually to RecoveryRx royalties
Strategic impact: Accelerates global clinical uptake
Combined Realistic Annual Revenue
Mid‑range scenario:
ActiPatch: $800K
RecoveryRx: $600K
Veterinary: $240K
Vagus nerve: $1.2M
Phantom limb multiplier: $300K
Total realistic annual revenue: $3.1M – $4M
Best‑case scenario: $6M – $10M+, PPS = .40 (P/E = 1000)
Why This Model Finally Works
Sree Koneru (Viant):
Scalable FDA‑grade manufacturing
Lower cost of goods
Ability to fulfill large retail orders
Keith Nalepka (VLMS Global Healthcare):
Opens global clinical channels
Drives hospital adoption
Adds veterinary and specialty markets
Electrome:
Drives consumer retail rollout
Invests in branding, packaging, displays
BIEL:
Provides patents, technology, and IP backbone
For the first time, BIEL has the ecosystem to become a multi‑stream royalty company instead of a single‑product OTC struggler.
Electrome’s JPM + DARPA Momentum: A Major Validation Signal
Electrome’s CMO, Dr. Nevena Zubcevik, reported strong investor engagement at JPM 2026 and highlighted alignment with DARPA‑related national security innovation.
This matters because it confirms:
1. Electrome is well‑funded, credible, and ambitious
They are presenting at JPM, raising capital, and engaging with government‑aligned programs.
2. Electrome is likely to push ActiPatch into clinical + government channels
DARPA interest aligns with:
Vagus nerve stimulation
Phantom limb pain
Battlefield medicine
Non‑pharmaceutical pain control
Exactly where BIEL’s IP sits.
3. Government‑funded clinical validation becomes more likely
This opens doors to:
Grants
Military trials
VA adoption
DoD procurement
4. BIEL’s technology fits into a larger bioelectric medicine ecosystem
Electrome is publicly positioning itself at the frontier of bioelectric medicine — the same domain BIEL has patented for years.
This increases the probability that the upper end of BIEL’s revenue model becomes achievable.
Bottom Line: What This Means for BIEL
The revenue numbers don’t change —
but the probability of achieving them just increased.
Electrome’s momentum confirms:
BIEL’s IP is strategically aligned
Bioelectric medicine is gaining institutional traction
Government channels are opening
Clinical validation is accelerating
Retail rollout is backed by real funding
The model is intact. The confidence level is rising.
BIEL Becomes the Story Stock for 2026 @ PPS = .003
A move to .003 represents a 3,000% gain from .0001 — outperforming the 10‑year percentage gains of Apple, Amazon, Netflix, Microsoft, Google, and others. We’re already 10% of the way there. The moment this breakout occurs, BIEL/Electrome will receive millions of dollars in free publicity, igniting global awareness and accelerating sales. When the narrative flips, big money will chase the stock.
The BIEL Quantum Leap
BIEL is positioned to achieve in months what took Amazon, Netflix, Apple, Google, Tesla, and Nvidia decades to accomplish.
If BIEL delivers $2.5M in net profit and convinces investors of sustainable, disruptive growth, it could theoretically command a $2.5B market cap (PPS = $0.10). That’s a 1000× P/E multiple, driven by narrative momentum and valuation leverage — similar to Nvidia’s 100,000% rise from its all‑time low.
The quantum leap hinges on one thing:
Transforming investor perception.
If BIEL aligns profitability with a bold, disruptive vision (hello Electrome), the market could reward it with exponential valuation leverage — turning a sub‑penny stock into a medtech powerhouse.
Profitability Is Within Reach
BIEL has already demonstrated how close it is:
Q3 2021 net income: $22,381
Revenue: $414,700 (includes: $100K COVID relief)
Given BIEL’s ultra‑lean operating model, sustained profitability is not theoretical — it’s imminent.
BIEL’s Fastest Path to Success
1. Hit $400K in quarterly revenue
Historical data shows this level supports consistent profitability.
Even the expectation of reaching $400K/quarter could push PPS to copper.
2. Reach $1.5M in annual revenue
Confirms sustainable growth and strengthens investor confidence.
3. Leverage the new U.S. distributor
If investors value the partnership at even $300K, PPS exits the trips.
At a $1M valuation, PPS hits copper.
Share Price Projection
Once profitability is achieved (or imminent), PPS is projected to hit copper ($0.01+).
For every additional $2.5M in annual profit, PPS could rise by $0.01 (P/E = 100).
Valuation Scenarios
.001 — Technical breakout (Golden Cross .0003, Blue‑Sky .0006)
.003 — 3,000% gain when U.S. distributor news goes viral
.01 — Profitability confirmed
.02 — $5M profit
.04 — $10M profit (or $1M × 1000 P/E)
.10 — $25M profit (or $2.5M × 1000 P/E)
$1.00 — After debt payoff + buyback
Tax Advantage: A Hidden Accelerator
BIEL holds a $40M tax‑loss carryforward, meaning the first $40M in profits are tax‑free — accelerating net profitability and preserving cash during early growth.
BIEL’s Multi‑Stream Royalty Revenue Model
BIEL is no longer a single‑product company. It is evolving into a pure‑IP royalty engine with four monetizable product lines plus a clinical multiplier.
1️⃣ ActiPatch — Consumer Retail (Electrome‑Driven)
Where it sells: Pharmacies, online retail, wellness channels
Partner: Electrome
Royalty: ~$2 per unit
Volume: 250,000–1,000,000 units
Annual revenue to BIEL: $500K – $2M
2️⃣ RecoveryRx — Clinical / Post‑Surgical (VLMS‑Driven)
Where it sells: Hospitals, surgical centers, orthopedic practices
Partner: VLMS Global Healthcare
Royalty: $5–$7 per unit
Volume: 50,000–200,000 units
Annual revenue to BIEL: $300K – $1.4M
3️⃣ RecoveryRx Veterinary — High‑Margin Niche
Where it sells: Veterinary surgery, equine medicine, companion‑animal pain
Partner: VLMS or a dedicated veterinary distributor
Royalty: $5–$7.50 per unit
Volume: 20,000–100,000 units
Annual revenue to BIEL: $100K – $750K
4️⃣ Vagus Nerve Stimulation Device — Patent Pending
Applications: Anxiety, depression, PTSD, inflammation, autonomic dysfunction
Partner: Electrome, VLMS, or a new neuromodulation partner
Royalty: $10–$15 per unit
Volume: 50,000–500,000 units
Annual revenue to BIEL: $500K – $5M
5️⃣ Phantom Limb Pain Study — Clinical Validation Multiplier
Not a product — a value amplifier. It strengthens:
VA + military adoption
Insurance reimbursement
Hospital credibility
Pricing power
Revenue impact: +$300K annually to RecoveryRx royalties
Strategic impact: Accelerates global clinical uptake
Combined Realistic Annual Revenue
Mid‑range scenario:
ActiPatch: $800K
RecoveryRx: $600K
Veterinary: $240K
Vagus nerve: $1.2M
Phantom limb multiplier: $300K
Total realistic annual revenue: $3.1M – $4M
Best‑case scenario: $6M – $10M+, PPS = .40 (P/E = 1000)
Why This Model Finally Works
Sree Koneru (Viant):
Scalable FDA‑grade manufacturing
Lower cost of goods
Ability to fulfill large retail orders
Keith Nalepka (VLMS Global Healthcare):
Opens global clinical channels
Drives hospital adoption
Adds veterinary and specialty markets
Electrome:
Drives consumer retail rollout
Invests in branding, packaging, displays
BIEL:
Provides patents, technology, and IP backbone
For the first time, BIEL has the ecosystem to become a multi‑stream royalty company instead of a single‑product OTC struggler.
Electrome’s JPM + DARPA Momentum: A Major Validation Signal
Electrome’s CMO, Dr. Nevena Zubcevik, reported strong investor engagement at JPM 2026 and highlighted alignment with DARPA‑related national security innovation.
This matters because it confirms:
1. Electrome is well‑funded, credible, and ambitious
They are presenting at JPM, raising capital, and engaging with government‑aligned programs.
2. Electrome is likely to push ActiPatch into clinical + government channels
DARPA interest aligns with:
Vagus nerve stimulation
Phantom limb pain
Battlefield medicine
Non‑pharmaceutical pain control
Exactly where BIEL’s IP sits.
3. Government‑funded clinical validation becomes more likely
This opens doors to:
Grants
Military trials
VA adoption
DoD procurement
4. BIEL’s technology fits into a larger bioelectric medicine ecosystem
Electrome is publicly positioning itself at the frontier of bioelectric medicine — the same domain BIEL has patented for years.
This increases the probability that the upper end of BIEL’s revenue model becomes achievable.
Bottom Line: What This Means for BIEL
The revenue numbers don’t change —
but the probability of achieving them just increased.
Electrome’s momentum confirms:
BIEL’s IP is strategically aligned
Bioelectric medicine is gaining institutional traction
Government channels are opening
Clinical validation is accelerating
Retail rollout is backed by real funding
The model is intact. The confidence level is rising.
1
